517 related articles for article (PubMed ID: 34158243)
1. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
[TBL] [Abstract][Full Text] [Related]
2. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial.
Jia W; Zhang P; Zhu D; Duolikun N; Li H; Bao Y; Li X;
PLoS Med; 2021 Sep; 18(9):e1003754. PubMed ID: 34547030
[TBL] [Abstract][Full Text] [Related]
4. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
Rodríguez-Gutiérrez R; Montori VM
Circ Cardiovasc Qual Outcomes; 2016 Sep; 9(5):504-12. PubMed ID: 27553599
[TBL] [Abstract][Full Text] [Related]
5. Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials.
Mannucci E; Monami M; Candido R; Pintaudi B; Targher G;
Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1601-1608. PubMed ID: 32811736
[TBL] [Abstract][Full Text] [Related]
6. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.
Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
Diabetes Obes Metab; 2018 Sep; 20(9):2131-2139. PubMed ID: 29722116
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials.
Mannucci E; Naletto L; Vaccaro G; Silverii A; Dicembrini I; Pintaudi B; Monami M
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1027-1034. PubMed ID: 33618919
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus.
Kovatchev B; Umpierrez G; DiGenio A; Zhou R; Inzucchi SE
J Diabetes Sci Technol; 2015 Jun; 9(6):1227-35. PubMed ID: 26078255
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
10. Divergent effects of various diabetes drugs on cardiovascular prognosis.
Bell DS; Patil HR; O'Keefe JH
Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252
[TBL] [Abstract][Full Text] [Related]
11. Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sardar P; Udell JA; Chatterjee S; Bansilal S; Mukherjee D; Farkouh ME
J Am Heart Assoc; 2015 May; 4(5):. PubMed ID: 25944874
[TBL] [Abstract][Full Text] [Related]
12. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
[TBL] [Abstract][Full Text] [Related]
13. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
14. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Cosentino C; Monami M; Mannucci E; Pala L
Acta Diabetol; 2021 Apr; 58(4):401-410. PubMed ID: 32789691
[TBL] [Abstract][Full Text] [Related]
15. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Asbaghi O; Fatemeh N; Mahnaz RK; Ehsan G; Elham E; Behzad N; Damoon AL; Amirmansour AN
Pharmacol Res; 2020 Nov; 161():105098. PubMed ID: 32730903
[TBL] [Abstract][Full Text] [Related]
16. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
17. Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies.
Crabtree T; Ogendo JJ; Vinogradova Y; Gordon J; Idris I
Expert Rev Endocrinol Metab; 2022 May; 17(3):255-267. PubMed ID: 35614863
[TBL] [Abstract][Full Text] [Related]
18. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
19. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.
Ceriello A; Lucisano G; Prattichizzo F; La Grotta R; Franzén S; Svensson AM; Eliasson B; Nicolucci A
Cardiovasc Diabetol; 2022 Jan; 21(1):13. PubMed ID: 35073913
[TBL] [Abstract][Full Text] [Related]
20. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
